Based on our previous clinical findings on the Imaging and Phase I study using mAb B3 radiolabeled with 111IN and 90Y we have designed a follow up study of 90Y- B3 with autologous stem cell support for patients with metastatic breast carcinoma. The primary objectives of this study are to determine the dose-limiting toxicities and the maximum tolerated dose of 90Y-B3 when administered with stem cell support because 70 % of breast carcinomas express the B3 antigen. Secondary objectives are to evaluate the anti-tumor activity and the immunogenicity of this agent when given in marrow ablative doses. The study recently opened for accrual.

Agency
National Institute of Health (NIH)
Institute
Division of Basic Sciences - NCI (NCI)
Type
Intramural Research (Z01)
Project #
1Z01BC010291-05
Application #
6762974
Study Section
(LMB)
Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Basic Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code